AstraZeneca and Ranbaxy support partial summary judgment in Nexium litigation
MLex Summary: AstraZeneca and Ranbaxy reply in support of their motion for partial summary judgment on the basis of statute of limitations, arguing that claims regarding Ranbaxy's alleged exclusion from the generic...To view the full article, register now.
Already a subscriber? Click here to view full article